LakePharma Expands Antibody Center Into New 40,000 sq. ft. San Carlos Building

SAN CARLOS, Calif., Aug. 15, 2018 /PRNewswire/ -- LakePharma, the leading US-based biologics company specializing in antibody and protein engineering, cell line development, and protein production, announced today that it has successfully completed moving and consolidating all of its antibody services at its new location at 201 Industrial Rd., San Carlos, CA.   

"LakePharma is extremely happy to call this magnificent facility our new Antibody Center. With over 40,000 square feet of space specially designed for life science companies, we are able to consolidate all antibody services under one roof, with plenty space for growth. For our valued customers, it means better and more efficient service coordination, faster time lines and extra capacity for high volume and more complicated projects. LakePharma started with antibody production service nine years ago in a small building not far from this new facility. We remain committed to our vision of being the best US-based biologics company providing integrated antibody discovery, characterization and development solutions," said Hua Tu, Chairman and CEO.

About LakePharma

LakePharma is the leading US-based biologics company specializing in antibody engineering, antibody discovery, molecular engineering, protein chemistry, bioexpression, biofunction, bioprocessing, bioanalytics and µBIOMANUFACTURING℠ biologics manufacturing services for Phase 1 clinical trials. LakePharma focuses on integrated platforms to support projects throughout the drug discovery process. LakePharma offers dedicated client services and sophisticated software to provide real-time access to project data via a secure cloud-based portal. For more information, please visit www.lakepharma.com.

Contact
Walter Tian
VP, Commercial Operation
[email protected]

SOURCE LakePharma

Related Links

http://www.lakepharma.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED